Literature DB >> 9506768

Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues.

A W Brandenberger1, M K Tee, R B Jaffe.   

Abstract

The prognosis in ovarian carcinoma, the most lethal of the gynecologic neoplasms, is poor and has changed little in the last three decades. Only a small number respond to antiestrogen therapy, although the classic estrogen receptor, ER-alpha, has been identified in ovarian surface epithelium, from which approximately 90% of ovarian cancers originate. We have previously shown that ER-beta mRNA is most abundant in human fetal ovaries, suggesting that it might play an important role in ovarian development. Therefore, we investigated the mRNA levels of both ERs in normal ovaries, ovarian serous cystadenocarcinomas, granulosa cells from patients undergoing in vitro fertilization (IVF), the ovarian surface epithelium cell line IOSE-Van, and the ovarian cancer cell lines SKOV3, HEY and OCC1. Northern blots of normal and neoplastic ovaries were hybridized with an ER-beta riboprobe that spans the A/B domain. We detected two major hybridizing bands at approximately 8 and 10 kb. An RNase protection assay using the same probe revealed a single band of the expected size. Hybridizing the same blot with an ER-alpha riboprobe showed a strong hybridizing band at approximately 6.5 kb. In ovarian cancer samples, ER-beta mRNA level was decreased when compared to normal ovaries. Using 25 cycles of RT-PCR followed by Southern blotting, we found equal amounts of ER-alpha and -beta mRNAs in normal ovaries in all age groups from 33 to 75 years; however, in ovarian cancer tissue, the level of ER-alpha mRNA was similar or slightly higher, comparable to 10(3) to 10(4) copies of plasmid DNA, but ER-beta mRNA levels were markedly decreased. Granulosa cells from IVF patients expressed high levels of ER-beta mRNA. The OSE cell line expressed a low level of ER-alpha, detectable after 40 cycles of RT-PCR and no ER-beta mRNA. SKOV3 showed a low level of ER-alpha and -beta mRNAs, whereas OCC1 showed a low level of ER-beta and a relatively high level of ER-alpha. HEY did not contain detectable amounts of either ER after 40 cycles of RT-PCR. We found no evidence of differential splicing or major deletions in almost the entire coding region of ER-beta in either normal ovaries or tumor samples.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506768     DOI: 10.1210/jcem.83.3.4788

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  42 in total

Review 1.  Estrogen receptors and human disease: an update.

Authors:  Katherine A Burns; Kenneth S Korach
Journal:  Arch Toxicol       Date:  2012-05-31       Impact factor: 5.153

2.  Ovarian surface epitheliectomy in the non-human primate: continued cyclic ovarian function and limited epithelial replacement.

Authors:  Jay W Wright; Tanja Pejovic; Leigh Jurevic; Cecily V Bishop; Theodore Hobbs; Richard L Stouffer
Journal:  Hum Reprod       Date:  2011-03-18       Impact factor: 6.918

Review 3.  Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis.

Authors:  Gwendal Lazennec
Journal:  Cancer Lett       Date:  2006-01-18       Impact factor: 8.679

4.  Ginsenoside Rb1 inhibits tube-like structure formation of endothelial cells by regulating pigment epithelium-derived factor through the oestrogen beta receptor.

Authors:  K W Leung; L W T Cheung; Y L Pon; R N S Wong; N K Mak; T-P D Fan; S C L Au; J Tombran-Tink; A S T Wong
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

Review 5.  Regulation of 17β-hydroxysteroid dehydrogenases in cancer: regulating steroid receptor at pre-receptor stage.

Authors:  Mirja Rotinen; Joaquín Villar; Ignacio Encío
Journal:  J Physiol Biochem       Date:  2012-02-29       Impact factor: 4.158

6.  Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells.

Authors:  Pengming Sun; Jalid Sehouli; Carsten Denkert; Alexander Mustea; Dominique Könsgen; Ines Koch; Lihui Wei; Werner Lichtenegger
Journal:  J Mol Med (Berl)       Date:  2005-03-16       Impact factor: 4.599

7.  Negative regulation of estrogen signaling by ERβ and RIP140 in ovarian cancer cells.

Authors:  Aurélie Docquier; Aurélie Garcia; Julien Savatier; Abdel Boulahtouf; Sandrine Bonnet; Virginie Bellet; Muriel Busson; Emmanuel Margeat; Stéphan Jalaguier; Cathy Royer; Patrick Balaguer; Vincent Cavaillès
Journal:  Mol Endocrinol       Date:  2013-07-24

Review 8.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

9.  Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma.

Authors:  Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Keith Y Terada; Marc T Goodman
Journal:  Cancer Causes Control       Date:  2008-08-15       Impact factor: 2.506

10.  Conditionally immortal ovarian cell lines for investigating the influence of ovarian stroma on the estrogen sensitivity and tumorigenicity of ovarian surface epithelial cells.

Authors:  Feng Jiang; Beatriz O Saunders; Edward Haller; Sandra Livingston; Santo V Nicosia; Wenlong Bai
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jul-Aug       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.